3
|
Ferreira AV, Alarcon-Barrera JC, Domínguez-Andrés J, Bulut Ö, Kilic G, Debisarun PA, Röring RJ, Özhan HN, Terschlüsen E, Ziogas A, Kostidis S, Mohammed Y, Matzaraki V, Renieris G, Giamarellos-Bourboulis EJ, Netea MG, Giera M. Fatty acid desaturation and lipoxygenase pathways support trained immunity. Nat Commun 2023; 14:7385. [PMID: 37968313 PMCID: PMC10651900 DOI: 10.1038/s41467-023-43315-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Accepted: 11/06/2023] [Indexed: 11/17/2023] Open
Abstract
Infections and vaccines can induce enhanced long-term responses in innate immune cells, establishing an innate immunological memory termed trained immunity. Here, we show that monocytes with a trained immunity phenotype, due to exposure to the Bacillus Calmette-Guérin (BCG) vaccine, are characterized by an increased biosynthesis of different lipid mediators (LM) derived from long-chain polyunsaturated fatty acids (PUFA). Pharmacological and genetic approaches show that long-chain PUFA synthesis and lipoxygenase-derived LM are essential for the BCG-induced trained immunity responses of human monocytes. Furthermore, products of 12-lipoxygenase activity increase in monocytes of healthy individuals after BCG vaccination. Grasping the underscoring lipid metabolic pathways contributes to our understanding of trained immunity and may help to identify therapeutic tools and targets for the modulation of innate immune responses.
Collapse
Affiliation(s)
- Anaísa V Ferreira
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands.
- Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto, 4050-313, Porto, Portugal.
| | | | - Jorge Domínguez-Andrés
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands
| | - Özlem Bulut
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands
| | - Gizem Kilic
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands
| | - Priya A Debisarun
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands
| | - Rutger J Röring
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands
| | - Hatice N Özhan
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands
| | - Eva Terschlüsen
- Department of Medical Microbiology, Radboud University Medical Centre, 6500HB, Nijmegen, The Netherlands
| | - Athanasios Ziogas
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands
| | - Sarantos Kostidis
- Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZA, Leiden, the Netherlands
| | - Yassene Mohammed
- Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZA, Leiden, the Netherlands
| | - Vasiliki Matzaraki
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands
| | - George Renieris
- 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | | | - Mihai G Netea
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Nijmegen Medical Center, 6500HB, Nijmegen, The Netherlands
- Department for Immunology and Metabolism, Life and Medical Sciences Institute (LIMES), University of Bonn, 53115, Bonn, Germany
| | - Martin Giera
- Center for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZA, Leiden, the Netherlands.
| |
Collapse
|
4
|
Wang W, Liang M, Wang L, Bei W, Guo J. 15-Hydroxyprostaglandin dehydrogenase inhibitor SW033291 ameliorates hepatic abnormal lipid metabolism, ER stress, and inflammation through PGE 2/EP4 in T2DM mice. Bioorg Chem 2023; 137:106646. [PMID: 37285764 DOI: 10.1016/j.bioorg.2023.106646] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 04/13/2023] [Accepted: 05/29/2023] [Indexed: 06/09/2023]
Abstract
Type 2 diabetes mellitus (T2DM) is a rapidly growing epidemic that results in increased morbidity, mortality, and soaring medical costs. Prostaglandin E2 (PGE2), a vital lipid mediator, has been reported to protect against hepatic steatosis, inflammation, endoplasmic reticulum (ER) stress, and insulin resistance, indicating its potential therapeutic role in T2DM. PGE2 can be degraded by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). SW033291, an inhibitor of 15-PGDH, has been reported to increase PGE2 levels, however, the effect of SW033291 in T2DM remains to be explored. This study aims to evaluate whether SW033291 protects against T2DM and explore its potential mechanisms. A T2DM mouse model was established through high-fat diet/streptozotocin injection, while palmitic acid-treated mouse primary hepatocytes were used as insulin-resistant cell models. SW033291 treatment reduced body weight, fat weight, fasting blood glucose, and improved impaired glucose tolerance and insulin resistance in T2DM mice. More importantly, SW033291 alleviated steatosis, inflammation, and ER stress in the liver of T2DM mice. Mechanistically, SW033291 decreased the expressions of SREBP-1c and ACC1, and increased the expression of PPARα in T2DM mice. Additionally, SW033291 inhibited NF-κB and eIF2α/CHOP signaling in T2DM mice. Further, we showed that the protective effects of SW033291 on the above-mentioned pathophysiological processes could be hindered by inhibition of the PGE2 receptor EP4. Overall, our study reveals a novel role of SW033291 in alleviating T2DM and suggests its potential as a new therapeutic strategy for T2DM.
Collapse
Affiliation(s)
- Weixuan Wang
- Traditional Chinese Medicine Research Institute, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China; Guangdong Provincial Research Center of Integration of Traditional Chinese Medicine and Western Medicine in Metabolic Diseases, Guangzhou, Guangdong Province, China; Key Laboratory of Glucolipid Metabolic Diseases, Ministry of Education, Guangzhou, Guangdong Province, China; Guangdong Provincial TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China
| | - Mingjie Liang
- Traditional Chinese Medicine Research Institute, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China; Guangdong Provincial Research Center of Integration of Traditional Chinese Medicine and Western Medicine in Metabolic Diseases, Guangzhou, Guangdong Province, China; Key Laboratory of Glucolipid Metabolic Diseases, Ministry of Education, Guangzhou, Guangdong Province, China; Guangdong Provincial TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China
| | - Lexun Wang
- Traditional Chinese Medicine Research Institute, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China; Guangdong Provincial Research Center of Integration of Traditional Chinese Medicine and Western Medicine in Metabolic Diseases, Guangzhou, Guangdong Province, China; Key Laboratory of Glucolipid Metabolic Diseases, Ministry of Education, Guangzhou, Guangdong Province, China; Guangdong Provincial TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China
| | - Weijian Bei
- Traditional Chinese Medicine Research Institute, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China; Guangdong Provincial Research Center of Integration of Traditional Chinese Medicine and Western Medicine in Metabolic Diseases, Guangzhou, Guangdong Province, China; Key Laboratory of Glucolipid Metabolic Diseases, Ministry of Education, Guangzhou, Guangdong Province, China; Guangdong Provincial TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China
| | - Jiao Guo
- Traditional Chinese Medicine Research Institute, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China; Guangdong Provincial Research Center of Integration of Traditional Chinese Medicine and Western Medicine in Metabolic Diseases, Guangzhou, Guangdong Province, China; Key Laboratory of Glucolipid Metabolic Diseases, Ministry of Education, Guangzhou, Guangdong Province, China; Guangdong Provincial TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China.
| |
Collapse
|
6
|
Rubino M, Travers JG, Headrick AL, Enyart BT, Lemieux ME, Cavasin MA, Schwisow JA, Hardy EJ, Kaltenbacher KJ, Felisbino MB, Jonas E, Ambardekar AV, Bristow MR, Koch KA, McKinsey TA. Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart. Circ Res 2023; 132:10-29. [PMID: 36475698 DOI: 10.1161/circresaha.122.321475] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Organ fibrosis due to excessive production of extracellular matrix by resident fibroblasts is estimated to contribute to >45% of deaths in the Western world, including those due to cardiovascular diseases such as heart failure. Here, we screened for small molecule inhibitors with a common ability to suppress activation of fibroblasts across organ systems. METHODS High-content imaging of cultured cardiac, pulmonary, and renal fibroblasts was used to identify nontoxic compounds that blocked induction of markers of activation in response to the profibrotic stimulus, transforming growth factor-β1. SW033291, which inhibits the eicosanoid-degrading enzyme, 15-hydroxyprostaglandin dehydrogenase, was chosen for follow-up studies with cultured adult rat ventricular fibroblasts and human cardiac fibroblasts (CF), and for evaluation in mouse models of cardiac fibrosis and diastolic dysfunction. Additional mechanistic studies were performed with CFs treated with exogenous eicosanoids. RESULTS Nine compounds, including SW033291, shared a common ability to suppress transforming growth factor-β1-mediated activation of cardiac, pulmonary, and renal fibroblasts. SW033291 dose-dependently inhibited transforming growth factor-β1-induced expression of activation markers (eg, α-smooth muscle actin and periostin) in adult rat ventricular fibroblasts and normal human CFs, and reduced contractile capacity of the cells. Remarkably, the 15-hydroxyprostaglandin dehydrogenase inhibitor also reversed constitutive activation of fibroblasts obtained from explanted hearts from patients with heart failure. SW033291 blocked cardiac fibrosis induced by angiotensin II infusion and ameliorated diastolic dysfunction in an alternative model of systemic hypertension driven by combined uninephrectomy and deoxycorticosterone acetate administration. Mechanistically, SW033291-mediated stimulation of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling was required for the compound to block CF activation. Of the 12 exogenous eicosanoids that were tested, only 12(S)-hydroxyeicosatetraenoic acid, which signals through the G protein-coupled receptor, GPR31, recapitulated the suppressive effects of SW033291 on CF activation. CONCLUSIONS Inhibition of degradation of eicosanoids, arachidonic acid-derived fatty acids that signal through G protein-coupled receptors, is a potential therapeutic strategy for suppression of pathological organ fibrosis. In the heart, we propose that 15-hydroxyprostaglandin dehydrogenase inhibition triggers CF-derived autocrine/paracrine signaling by eicosanoids, including 12(S)-hydroxyeicosatetraenoic acid, to stimulate extracellular signal-regulated kinase 1/2 and block conversion of fibroblasts into activated cells that secrete excessive amounts of extracellular matrix and contribute to heart failure pathogenesis.
Collapse
Affiliation(s)
- Marcello Rubino
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Joshua G Travers
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Alaina L Headrick
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Blake T Enyart
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | | | - Maria A Cavasin
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Jessica A Schwisow
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Elizabeth J Hardy
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Keenan J Kaltenbacher
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Marina B Felisbino
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Eric Jonas
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Amrut V Ambardekar
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Michael R Bristow
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Keith A Koch
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| | - Timothy A McKinsey
- From the Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., J.A.S., E.J.H., K.J.K., M.B.F., E.J., A.V.A., M.R.B., K.A.K., T.A.M.).,Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora (M.R., J.G.T., A.L.H., B.T.E., M.A.C., E.J.H., K.J.K., M.B.F., A.V.A., M.R.B., K.A.K., T.A.M.)
| |
Collapse
|